ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance 111In-DTPA-hEGF auger electron radiation therapy

Journal of Nuclear Medicine

Volumn 52, Issue 5, 2011, Pages 776-783

  Cornelissen, Bart ^a   Darbar, Sonali ^a   Hernandez, Rebecca ^a   Kersemans, Veerle ^a   Tullis, Iain ^a   Barber, Paul R ^a   Smart, Sean ^a   Vojnovic, Borivoj ^a   Reilly, Raymond ^b,c   Vallis, Katherine A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

111In; Auger electrons; EGF; EGFR; FRET; Prenyltransferase inhibitor; Radioimmunotherapy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE PENTETATE INDIUM IN 111; L 778123; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL NUCLEUS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; ELECTRON THERAPY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DIMETHYLALLYLTRANSTRANSFERASE; ELECTRONS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMIDAZOLES; MICE; PENTETIC ACID; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 79955768559     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084392     Document Type: Article

References (40)

1. Zahorowska B, Crowe PJ, Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol. 2009;135:1137-1148.
2. 111In-DTPA-hEGF. J Nucl Med. 2008;49:1353-1361.
3. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med. 2003;44:1469-1478.
4. 111In]DTPA-hEGF. Nucl Med Biol. 2009;34:887-896.
5. Reilly RM, Kiarash R, Cameron RG, et al. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med. 2000;41:429-438. (Pubitemid 30133961)
6. 111In for radiotherapeutic applications. J Nucl Med. 2004;45:701-708.
7. Cornelissen B, Vallis KA. Targeting the nucleus: an overview of Auger-electron radionuclide therapy. Curr Drug Discov Technol. 2010;7:263-279.
8. Howell RW. Auger processes in the 21st century. Int J Radiat Biol. 2008;84:959-975.
9. 111In. J Nucl Med. 2009;50:582-590.
10. Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun. 2009;30:5-15.
11. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol. 2004;80:789-803. (Pubitemid 40138140)
12. Bailey KE, Costantini DL, Cai Z, et al. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. J Nucl Med. 2007;48:1562-1570. (Pubitemid 47397407)
13. 125I]iodo-2′-deoxyuridine. Acta Oncol. 2000;39:731-737.
14. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006;12:904-916.
15. 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol. 2008;35:645-653.
16. Peter M, Ameer-Beg SM, Hughes MK, et al. Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptor-kinase interactions. Biophys J. 2005;88:1224-1237. (Pubitemid 40975950)
17. Wallrabe H, Periasamy A. Imaging protein molecules using FRET and FLIM microscopy. Curr Opin Biotechnol. 2005;16:19-27. (Pubitemid 40249755)
18. Barber PR, Ameer-Beg SM, Gilbey J, et al. Multiphoton time-domain FLIM: Practical application to protein-protein interactions using global analysis. J R Soc Interface. 2009;6:S93-S106.
19. Cornelissen B, Thonissen T, Kersemans V, et al. Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status. Nucl Med Biol. 2004;31:679-689. (Pubitemid 38887749)
20. 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol. 2007;34:37-46.
21. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cancer Biother Radiopharm. 2009;24:163-173.
22. Edelman MJ, Quam H, Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol. 2001;48:141-144. (Pubitemid 32710225)
23. Burke P, Schooler K, Wiley HS. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001;12:1897-1910.
24. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. Nuclearcytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem. 2006;98:1570-1583. (Pubitemid 44141861)
25. Huo L, Wang YN, Xia W, et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus Proc Natl Acad Sci USA. 2010;107:16125-16130.
26. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat. 2006;95:211-218.
27. Onono FO, Morgan MA, Spielmann HP, et al. A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol Cell Proteomics. 2010;9:742-751.
28. Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol. 2009;10:609-622.
29. Wherlock M, Gampel A, Futter C, Mellor H. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J Cell Sci. 2004;117:3221-3231. (Pubitemid 39139908)
30. Brunner TB, Hahn SM, McKenna WG, Bernhard EJ. Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol. 2004;180:731-740. (Pubitemid 40022280)
31. Qayum N, Muschel RJ, Im JH, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 2009;69:6347-6354.
32. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res. 2005;65:3671-3681. (Pubitemid 40616344)
33. Warnberg F, White D, Anderson E, et al. Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res. 2006;8:R21.
34. Yao R, Wang Y, Lu Y, et al. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets. Carcinogenesis. 2006;27:1420-1431. (Pubitemid 43985417)
35. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2008;314:3093-3106.
36. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 2003;63:1130-1137.
37. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled affibody molecules. J Nucl Med. 2009;50:1131-1139.
38. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res. 2007;5:195-201. (Pubitemid 46424000)
39. 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med. 2008;49:1498-1505.
40. Graham KA, Richardson CL, Minden MD, Trent JM, Buick RN. Varying degrees of amplification of the N-ras oncogene in the human breast cancer cell line MCF-7. Cancer Res. 1985;45:2201-2205. (Pubitemid 15024329)